VYNE Therapeutics Inc. Common Stock (VYNE) Stock Price

VYNEStock

$28.56+79.25%52W

Market Cap$19.07M

P/E—

PEG Ratio—

Div yield—

Beta-0.75

VYNE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-18.81%

Price vs S&P 500 (4W)-27.91%

VGM Score46.72

Book Value / Share (Quarterly)$36.93

P/TBV (Annual)1.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.90%

Cash Flow / Share (Quarterly)$-0.77

Price vs S&P 500 (YTD)-14.52%

Gross Margin (TTM)81.03%

Net Profit Margin (TTM)-8328.25%

EPS (TTM)$-0.50

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-9.05

Revenue Growth (5Y)-36.39%

EPS (Annual)$-30.96

ROI (Annual)-95.38%

Gross Margin (Annual)93.38%

Net Profit Margin (5Y Avg)-1388.79%

Cash / Share (Quarterly)$36.92

Revenue Growth QoQ (YoY)-31.74%

ROA (Last FY)-87.81%

Revenue Growth TTM (YoY)111.03%

EBITD / Share (TTM)$-9.38

ROE (5Y Avg)-207.48%

Operating Margin (TTM)-8590.68%

Cash Flow / Share (Annual)$-49.70

P/B Ratio3.79x

P/B Ratio (Quarterly)0.81x

Net Income / Employee (Annual)$-2,648,300

EV / Revenue (TTM)151.69x

Net Interest Coverage (TTM)-6.96x

ROA (TTM)-62.70%

EPS Growth QoQ (YoY)35.68%

EPS Incl Extra (Annual)$-30.96

Current Ratio (Annual)12.53x

Quick Ratio (Quarterly)20.17x

3-Month Avg Trading Volume0.05M

52-Week Price Return79.25%

Revenue / Employee (TTM)$29,500,000,000

Tangible BV / Share (Quarterly)$3.48

P/S Ratio (Annual)164.03x

Asset Turnover (Annual)0.02x

52-Week High$46.95

Operating Margin (5Y Avg)-1381.70%

EPS Excl Extra (Annual)$-30.96

CapEx CAGR (5Y)63.54%

Tangible BV CAGR (5Y)-9.69%

26-Week Price Return-1.88%

Quick Ratio (Annual)12.11x

13-Week Price Return-11.75%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)20.86x

Enterprise Value$68.86M

Revenue / Share Growth (5Y)-59.85%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-43.15%

Revenue / Employee (Annual)$57,000

Pretax Margin (Annual)-4689.82%

Cash / Share (Annual)$36.05

3-Month Return Std Dev121.97%

Net Income / Employee (TTM)$-2,456,833,000,000

ROE (Last FY)-95.38%

Net Interest Coverage (Annual)-8.77x

EPS Basic Excl Extra (Annual)$-30.96

Receivables Turnover (TTM)0.98x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-9.89

Receivables Turnover (Annual)0.12x

ROI (TTM)-111.49%

P/S Ratio (TTM)158.10x

Pretax Margin (5Y Avg)-1390.88%

Revenue / Share (Annual)$0.67

Tangible BV / Share (Annual)$9.73

Price vs S&P 500 (52W)63.27%

EPS Growth TTM (YoY)-5.04%

Year-to-Date Return-1.10%

5-Day Price Return10.56%

EPS Normalized (Annual)$-30.96

ROA (5Y Avg)-105.32%

Net Profit Margin (Annual)-4646.14%

Month-to-Date Return-12.99%

Cash Flow / Share (TTM)$-9.09

EBITD / Share (Annual)$-34.75

Operating Margin (Annual)-5219.12%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-131.84%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-9.05

P/TBV (Quarterly)4.86x

P/B Ratio (Annual)0.70x

Inventory Turnover (TTM)0.21x

Pretax Margin (TTM)-8324.58%

Book Value / Share (Annual)$41.66

Price vs S&P 500 (13W)-15.65%

Beta-0.75x

Revenue / Share (TTM)$0.11

ROE (TTM)-89.10%

52-Week Low$16.04

vGradeF

gGradeC

mGradeB

vgmGradeC

VYNE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Feb 27, 2026	-$11.50	-$5.50	+52.17%(+$6.00)
Q3 2025	Nov 6, 2025	-$6.50	-$8.50	-30.77%(-$2.00)
Q2 2025	Aug 14, 2025	-$11.17	-$6.50	+41.79%(+$4.67)
Q1 2025	May 8, 2025	-$14.50	-$10.00	+31.03%(+$4.50)

VYNE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.90

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VYNEVYNE Therapeutics Inc. Common Stock	F	C	B	158.1x	111.0%	81.0%	—	$28.56
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About VYNE Therapeutics Inc. Common Stock

VYNE Therapeutics is a biopharmaceutical company developing therapies for immuno-inflammatory skin conditions. The company markets dermatology products AMZEEQ and ZILXI while advancing FMX114 as its lead pipeline candidate for atopic dermatitis treatment. VYNE also maintains pre-clinical programs targeting BET inhibitors for potential future applications.